North America Genetic Testing Market Size (2024 - 2029)

The North America Genetic Testing Market is projected to experience significant growth over the forecast period, driven by an increasing demand for personalized genetic testing services and a rise in the prevalence of chronic and genetic disorders. The market's expansion is further supported by the approval and launch of new products by regulatory bodies, which enhance accessibility to genetic testing. Although the COVID-19 pandemic initially slowed the market due to restricted healthcare services, the market has shown recovery and is expected to continue its upward trajectory. The challenges posed by the pandemic, particularly in clinical trials for rare diseases, have underscored the need for innovative approaches, thereby influencing market dynamics.

Market Size of North America Genetic Testing Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
North America Genetic Testing Market  Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 7.78 Billion
Market Size (2029) USD 12.54 Billion
CAGR (2024 - 2029) 10.02 %

Major Players

North America Genetic Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

North America Genetic Testing Market Analysis

The North America Genetic Testing Market size is estimated at USD 7.78 billion in 2024, and is expected to reach USD 12.54 billion by 2029, growing at a CAGR of 10.02% during the forecast period (2024-2029).

The COVID-19 pandemic left a significant impact on the growth of the genetic testing market. According to the study published in Prenatal Diagnosis in March 2021, the COVID-19 pandemic influenced pregnant women's decisions about prenatal genetic testing. Patients' access to and use of prenatal genetic tests may have been impacted by the pandemic. According to a study published in January 2021 by a group of researchers from the United States, there was an urgent need for the development of approaches that can reduce the serious challenges affecting patients with rare and undiagnosed diseases and families. The challenges include diagnostic and/or prognostic uncertainty coupled with medical complexity leading to poor health outcomes. In addition, clinical trials focused on rare diseases had also been affected by the COVID-19 pandemic. The pandemic created several challenges for clinical trials. The challenges associated with finding, recruiting, and retaining patients with rare diseases majorly impacted clinical trials. The genetic testing market was severely impacted by the COVID-19 outbreak but has recovered in the two years to show strong growth in the post pandemic era.

The market is growing constantly owing to factors, like increasing demand for personalized genetic testing services in the region and the rise in the prevalence of chronic and genetic disorders. According to the CDC, most clinics and hospitals have restricted in-person delivery of non-essential healthcare services, including genetic counseling, to minimize coronavirus transmission. Hence, though the market studied had slowed down due to the pandemic, the situation is expected to improve gradually.

According to the World Federation of Hemophilia 2021 Report, there were about 14,816 patiens with hemophilia (hemophilia A - 11,790 and hemophilia B - 3,026) in the United States in 2020 and 3,924 patients with hemophilia in Canada in 2020 (hemophilia A - 3,223 and hemophilia B - 701) . Such a high number of hemophilia cases in these regions is expected to drive the growth of the market due to the higher adoption of therapies for hemophilia. Thus, increasing genetic diseases in the region is driving the need for genetic testing.

The increasing product approvals by the USFDA and subsequent launches are anticipated to drive the market's growth in North America. For instance, in October 2021, F. Hoffmann-La Roche Ltd launched AVENIO Tumor Tissue CGP Kit, a comprehensive genomic profiling kit to make tailored cancer research more accessible. Thus, given the growing cancer incidence and strategies taken ahead by key players in the region, the genetic testing market is expected to grow significantly over the forecast period in North America.

North America Genetic Testing Industry Segmentation

As per the scope of the report, a genetic test is performed to identify the presence of a gene, with a particular sequence in the genome. The gene can be either identified directly through sequencing or can be identified indirectly through various methods. These genetic tests are carried out to assess the risk of an individual developing a certain disease. 

The North American genetic testing market is segmented by type (carrier testing, diagnostic testing, newborn screening, predictive and presymptomatic testing, prenatal testing, and other types), disease (Alzheimer's disease, cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, thalassemia, Huntington's disease, and rare diseases), technology (cytogenetic testing, biochemical testing, and molecular testing), and country (United States, Canada, and Mexico). The report offers the value (in USD million) for the above segments.

By Type
Carrier Testing
Diagnostic Testing
Newborn Screening
Predictive and Presymptomatic Testing
Prenatal Testing
Other Types
By Diseases
Alzheimer's Disease
Cancer
Cystic Fibrosis
Sickle Cell Anemia
Duchenne Muscular Dystrophy
Thalassemia
Huntington's Disease
Rare Diseases
By Technology
Cytogenetic Testing
Biochemical Testing
Molecular Testing
By Country
United States
Canada
Mexico
Need A Different Region Or Segment?
Customize Now

North America Genetic Testing Market Size Summary

The North America genetic testing market is poised for substantial growth, driven by increasing demand for personalized genetic testing services and a rising prevalence of chronic and genetic disorders. The market experienced a slowdown due to the COVID-19 pandemic, which affected access to prenatal genetic testing and posed challenges for clinical trials focused on rare diseases. However, the market has shown resilience and is expected to recover and expand significantly over the forecast period. The high incidence of conditions such as hemophilia and cancer, coupled with advancements in genetic testing technologies and increased product approvals by regulatory bodies like the USFDA, are key factors propelling market growth. The introduction of innovative testing kits and the growing awareness of genetic disorders further contribute to the market's positive outlook.

The competitive landscape of the North American genetic testing market is characterized by the presence of both international and local companies, including prominent players such as 23&Me Inc., Abbott Laboratories, and Illumina Inc. These companies are actively involved in expanding their genetic testing capabilities and launching new products to meet the growing demand. Collaborations and strategic acquisitions, such as Invitae's partnership with Simons Searchlight and Eurofins' acquisition of DNA Diagnostics Center, highlight the industry's focus on enhancing research and testing capabilities. The market's growth is also supported by technological advancements and increased investment in healthcare infrastructure, particularly in the United States, where the demand for genetic testing services is expected to rise significantly.

Explore More

North America Genetic Testing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Emphasis on Early Disease Detection and Prevention

      2. 1.2.2 Growing Demand for Personalized Medicine

      3. 1.2.3 Increasing Application of Genetic Testing in Oncology

    3. 1.3 Market Restraints

      1. 1.3.1 High Costs of Genetic Testing

      2. 1.3.2 Potentially Adverse Personal or Societal Consequences

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. Market Segmentation (Market Size by Value - USD million)

    1. 2.1 By Type

      1. 2.1.1 Carrier Testing

      2. 2.1.2 Diagnostic Testing

      3. 2.1.3 Newborn Screening

      4. 2.1.4 Predictive and Presymptomatic Testing

      5. 2.1.5 Prenatal Testing

      6. 2.1.6 Other Types

    2. 2.2 By Diseases

      1. 2.2.1 Alzheimer's Disease

      2. 2.2.2 Cancer

      3. 2.2.3 Cystic Fibrosis

      4. 2.2.4 Sickle Cell Anemia

      5. 2.2.5 Duchenne Muscular Dystrophy

      6. 2.2.6 Thalassemia

      7. 2.2.7 Huntington's Disease

      8. 2.2.8 Rare Diseases

    3. 2.3 By Technology

      1. 2.3.1 Cytogenetic Testing

      2. 2.3.2 Biochemical Testing

      3. 2.3.3 Molecular Testing

    4. 2.4 By Country

      1. 2.4.1 United States

      2. 2.4.2 Canada

      3. 2.4.3 Mexico

North America Genetic Testing Market Size FAQs

The North America Genetic Testing Market size is expected to reach USD 7.78 billion in 2024 and grow at a CAGR of 10.02% to reach USD 12.54 billion by 2029.

In 2024, the North America Genetic Testing Market size is expected to reach USD 7.78 billion.

North America Genetic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)